Monette Aujay
Nivalis Therapeutics (United States)(US)
Publications by Year
Research Areas
Ubiquitin and proteasome pathways, Protein Degradation and Inhibitors, Peptidase Inhibition and Analysis, Lung Cancer Research Studies, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → The complete genome of the hyperthermophilic bacterium Aquifex aeolicus(1998)1,105 cited
- → Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome(2007)669 cited
- → A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis(2009)590 cited
- → A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo(2015)565 cited
- → Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome(2009)320 cited
- → Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)(2009)271 cited
- → Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy(2000)270 cited
- → A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma(2010)216 cited
- → A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions(2017)154 cited
- → PR‐924, a selective inhibitor of the immunoproteasome subunit LMP‐7, blocks multiple myeloma cell growth both in vitro and in vivo(2010)112 cited